Heart disease kills more people globally each year than any other condition. For decades, treatment has largely been limited to managing symptoms with medications aimed at reducing strain on the failing heart. None of these approaches address the underlying biological factors driving cardiac disease; however,gene therapy offers a different approach.
Cardiac gene therapy enables the delivery of corrective genetic instructions directly to cardiac tissue. This revolutionary treatment can help rewrite gene codes associated with heart disease rather than simply managing the symptoms.
Safety profiles for Phase 1 trials have been generally acceptable, but what do other studies say about the safety of this treatment, and what does the future of cardiac gene therapy look like?
The Evolution of Gene Carriers
The first generation of cardiac gene therapy utilized adenoviral vectors. These modified viruses were clinically stripped of their disease-causing mechanisms, becoming delivery vehicles through which the corrective genes could be delivered to cardiac tissue.
Early researchers found adenoviruses appealing because they could infect a variety of cells, including cardiomyocytes. However, even after engineering, adenoviral vectors kept viral genome fragments that often triggered immune and inflammatory responses. As a result, transgene expression returned to baseline after administration, making durable treatment effects difficult to achieve.
Moreover, some patients’ immune systems began recognizing and attacking the vector, so repeat dosing became ineffective, and in some cases, life-threatening. , These limitations led scientists toward adeno-associated viruses (AAVs), which quickly became the most dominant cardiac gene therapy delivery method.
Of the 13 known serotypes and wild-type variants, AAV1, 6, 8, and 9 offer the most promising outcomes for heart disease patients. In particular, AAV9 demonstrates the best transduction into cardiomyocytes, with high efficiency and stable gene expression. And while the tissue selectivity isn’t perfect, it’s substantially better than alternative delivery methods.
Adeno-Associated Viruses in Cardiac Gene Therapy
Unlike their predecessors, adeno-associated viruses are non-pathogenic in humans. That means they cause no known disease and trigger a much less substantial immune response compared to adenoviral vectors. Additionally, AAVs can maintain stable, long-term gene expression in heart tissues, making them optimal for cardiac gene therapy.
During AVV gene therapy treatments, the DNA enters the cardiomyocyte nucleus, where it persists outside the chromosome to express the therapeutic gene for long periods without integrating into the host genome.
Why the Body Fights Back
Immunity is a common factor underlying the safety and efficacy challenges of cardiac gene therapy. This is because the human immune system identifies and neutralizes foreign biological material, including viral vectors. However, when carefully engineered, AAVs can remain undetected in the body, and the body’s defenses respond accordingly.
Two key barriers remain: pre-existing immunity and an immune response triggered by the treatment. Many people have been naturally exposed to AAV, often without developing symptoms, and that exposure leaves behind neutralizing antibodies (NAbs) that bind to the AAV capsid and stop it from entering the cells. But even in patients without pre-existing immunity, AAV administration can still activate the same adaptive immune system.
A critical consequence of this immune response is that re-dosing is rendered impossible with current vector applications. Any subsequent doses of the same vector become rapidly neutralized once the immune system has encountered an AAC capsid. Meanwhile, even aggressive immunosuppression hasn’t effectively prevented NAbs after the first dose.
Researchers are now developing novel cardiotropic capsid variants that concentrate genetic material delivery in heart tissue while progressively reducing off-target uptake in liver cells. Speak with your cardiologist to learn more.
What Clinical Trials Tell Us About Cardiac Gene Therapy Safety
Most Phase 1 trials of cardiac gene therapy have reported acceptable safety profiles, many with manageable adverse effects. However, some critics argue that the accumulated clinical evidence paints a cautiously optimistic picture.
One example includes a Phase 1 dose-escalation trial, which evaluated a chimeric cardiotropic AAV vector in 11 patients with nonischemic cardiomyopathy and advanced heart disease. Investigators found no adverse events attributable to the study treatment, and the events that did occur were relatively mild.
However, the CUPID trial program provides a thought-provoking counterpoint. Its Phase 1/2a component confirmed AAV1 was safe in advanced heart failure patients, yet the larger, randomized CUPID 2 trial failed to meet its primary efficacy goals. Investigators found no significant difference in clinical outcomes between control and treated patients.
The takeaway from current clinical research is that AAV-derived cardiac gene therapy is generally safe and does not elicit catastrophic immune responses in carefully screened patients. However, long-term follow-up data is still required to fully understand the impact of novel AAVs on liver toxicity across all serotypes.
Cardiac Gene Therapy Risks
Immune-related injuries are among the most consistently documented concerns surrounding cardiac gene therapy. Liver enzyme elevations are often reported across clinical trials, even among patients who screen negative for NAbs. Immune-mediated liver injury can progress to acute liver failure and even death in some cases.
As a result, hepatic monitoring has become a non-negotiable aspect of safe trial design and execution. But the risk profile shifts again for therapies that extend beyond the scope of gene delivery into gene editing.
CRISPR-Cas9 tools can also introduce concerns about off-target effects when the editing enzyme cuts at unintended genome locations around similar sequences. In the heart, this could mean unintentional edits to genes responsible for structural proteins or electrical conduction. In pre-clinical studies, current CRISPR-Cas9 tools produce approximately two to five off-target edits per guide RNA used.
Future Directions: Where Gene Therapy for Heart Disease Is Headed
Cardiac gene therapy barriers, such as immune reactions, off-target genome editing, limited re-dosing, and imprecise delivery, are solvable because they are challenges of gene engineering. Measurable progress is being made on each frontier.
Immediate advances include optimized capsids using directed evolution, rational protein design, and machine learning. Scientists can utilize those approaches to better leverage synthetic AAV variants that preferentially target cardiomyocytes while limiting liver uptake. Pairing engineered capsids with synthetic, cardiomyocyte-specific promoters could ultimately provide an additional protective layer against vector particles that target liver cells.
Meanwhile, non-viral platforms for therapeutic gene delivery to heart cells are also advancing alongside advanced capsid engineering. For example, lipid nanoparticles can provide lower immunogenicity and increase payload capacity, but cardiac specificity remains problematic. Standard nanoparticles accumulate in the liver, but selective organ targeting nanoparticles and polymer-based adjuncts could provide an alternative in some cases.
Gene Editing Considerations
Base and prime gene editors make precise single-nucleotide DNA alterations without double-strand breaks, meaning they decrease the off-target risks associated with CRISPR-Cas9 tools and treatments. Moreover, AI-assisted guide RNA could help improve target accuracy, and other engineered virus-like particles could transiently deliver gene editing components that clear from the body before lasting antibody memory is consolidated.
These advancements in cardiac gene therapy represent a methodical dismantling of barriers that have defined heart disease treatments for decades. Talk to your doctor to learn more.
Patient Selection and Screening
Some heart disease patients are not candidates for cardiac gene therapy. Specialists must conduct thorough assessments to determine safety, efficacy, and eligibility. Pre-existing immunity is often the first screen due to the prevalence of AAV antibodies in the general population. Patients with trial-defined genetic thresholds above Nab titers are generally excluded.
Comprehensive candidate selection involves weighing disease severity, stage, and underlying genetic profiles. Patients with single-gene mutations are typically top candidates for cardiac gene therapies, and those with advanced cardiac disease are often prioritized as well.
Liver function is another crucial screening variable, as patients with pre-existing liver disease or compromised hepatic function could require additional interventions and monitoring. Eligibility criteria will likely continue to evolve as ongoing trials conclude and the candidate pool widens.
Takeaway
Once a distant promise, cardiac gene therapy with AAV vectors now represents a potential new chapter in the treatment of heart disease. However, these therapies remain on the frontier of modern medicine and long-term safety data is still emerging.
For patients with hereditary heart conditions or advanced heart failure, conventional treatments may not be enough. The clinical landscape changes quickly and frequently, and many of today’s clinical trials were not available a year ago.
Speak to a cardiologist who specializes in advanced heart failure, heart disease, or genetic cardiomyopathies to understand emerging therapies and discuss your heart health and care options.
Visit the Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI) to follow the latest developments in cardiac gene therapies and cardiovascular research.
